Focus: MedTrace is a Danish biotech specializing in organ perfusion imaging, with a focused pipeline in cardiovascular and neurological applications. The company is in active clinical development with a Phase 3 asset in coronary artery disease.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
MedTrace offers early-stage upside in a specialized imaging space, but severe data transparency gaps and minimal hiring suggest evaluating financial health and clinical readout timelines before committing.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for MedTrace
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from MedTrace's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Automatic volumetric estimates of the left and right atrium using dynamic PET.
Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in pre-clinical individuals with a hypertrophic cardiomyopathy pathogenic variant: results of the ENERGY trial.
Showing 5 of 8 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo